{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.8","upperLimit":"95.1","value":"92.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"}],"units":"Participants"}],"description":"The percentage of participants without any surgery at month 6 was equivalent to the number of participants without any surgery by month 6 divided by the number of cohort 2 participants who had an opportunity to complete 6 months of treatment, expressed as a percentage.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with surgically salvageable disease whose planned initial on-study surgery was associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy) were enrolled into cohort 2 and received denosumab 120 mg SC Q4W, starting on study day 1, plus loading doses of 120 mg SC on days 8 and 15 in the first month of treatment.","id":"OG000","title":"Cohort 2 (Denosumab 120 mg Q4W)"}],"paramType":"NUMBER","populationDescription":"The efficacy analysis set included all enrolled participants who were eligible for the study, and who received at least one dose of denosumab on the study. Analysis was performed on cohort 2 only for those who had the opportunity to be on-study for at least 6 months.","reportingStatus":"POSTED","timeFrame":"At month 6.","title":"Percentage of Participants Without Any On-Study Surgery at Month 6 for Cohort 2","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}